ADAM9 and early-onset autosomal dominant Alzheimer disease: On the contrary, in SY5Y neuroblastoma cells overexpressing APP, mimicking Alzheimer’s disease, treatment with ADAM9 pro-domains inhibited the activity of ADAM9 but reduced the production of Aβ peptides.